加载中
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
前收盘价
US$2.29
+US$0.09 · +4.09%
盘中时间采用ET。市场数据可能有所延迟。
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
日内区间
当前US$2.29
52周区间
当前US$2.29
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
57
合理估值
情绪
56
多空交织
风险
46
风险偏高
动量
41
中性
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
XBiotech Inc. is a biopharmaceutical firm specializing in the discovery, development, and commercialization of True Human monoclonal antibodies. Their primary focus involves building a robust pipeline of product candidates aimed at combating both inflammatory and infectious diseases. Furthermore, the company is advancing interleukin-1 alpha-based therapies, which are designed to address a broad spectrum of medical conditions such as cancer, stroke, heart attack, and arthritis. Interleukin-1 alpha itself plays a crucial role in biological processes like tissue breakdown, angiogenesis, blood clot formation, malaise, muscle wasting, and inflammation. Additionally, XBiotech is developing a True Human COVID-19 therapy specifically targeting mutant strains of the virus. Established in 2005, XBiotech Inc. maintains its headquarters in Austin, Texas.
日内区间
当前US$2.29
52周区间
当前US$2.29
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 401万 USD | 1839.4万 USD |
| 销货成本 | 168.6万 USD | — | — | 65.1万 USD | 582万 USD |
| 毛利 | −168.6万 USD | — | — | 335.9万 USD | 1257.4万 USD |
| 研究与开发 | 4739万 USD | 3775.7万 USD | 3284.8万 USD | 3154.4万 USD | 2826.8万 USD |
| 销售、一般及管理费用 | 829.5万 USD | 471.4万 USD | 466.2万 USD | 630.5万 USD | 938.8万 USD |
| 营业费用 | 5399.9万 USD | 4247.1万 USD | 3751万 USD | 3784.9万 USD | 3765.6万 USD |
| 利息收入 | 567.9万 USD | 981.2万 USD | 1042.1万 USD | 382.3万 USD | 46.7万 USD |
| 利息支出 | 8.8万 USD | 80.7万 USD | — | — | — |
| 折旧和摊销 | 168.6万 USD | 174.5万 USD | 174.4万 USD | 261.4万 USD | 264.8万 USD |
| 营业利润 | −5568.5万 USD | −4247.1万 USD | −3751万 USD | −3449万 USD | −2508.2万 USD |
| 净利润 | −4554万 USD | −3853.1万 USD | −2455.7万 USD | −3290万 USD | −1741.4万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
评级样本有限，仅3项
| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2021年7月15日 | US$2.50Special | 2021年7月16日 | 2021年7月23日 |
除息 2021年7月15日
US$2.50
Special
2021年7月16日登记 · 支付日 2021年7月23日
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
